Abstract
A phase II programme was carried out in both Europe and North America to evaluate the activity of topotecan administered as a 21-day continuous intravenous infusion to patients with recurrent ovarian cancer. The European results are reported here. Patients who had failed first line therapy with a platinum-based regimen received topotecan 0.4 mg/m2/day, as a 21-day infusion every 28 days. Patients were only permitted one prior regimen. 35 patients were enrolled and evaluable for response. 3 patients (8.6%) had a partial response to treatment (95% CI 1.8%, 23.1%) with a median time to response of 8.1 weeks and a median duration of response of 17.6 weeks. Response was also evaluated by CA125 and was also found to be 8%. For all 35 patients, median time to progression was 16.1 weeks and median survival was 43.6 weeks. The principal toxicity was myelosuppression although grade 4 neutropenia occurred in only 8.8% of patients (2.1% of courses) and infectious complications were relatively infrequent. Non-haematological toxicity was generally mild and mainly consisted of gastrointestinal events, alopecia and fatigue. A prolonged infusion of topotecan was well tolerated with a low incidence of severe neutropenia. Responses were seen in both North American and European patients. Response rates varied between the 2 studies possibly due to differences in patient demographics. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alberts DS, Green S, Hannigan EV, O’Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA and Jolles CJ (1992) Improved therapeutic index of carboplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide: final report by the Southwestern Oncology Group of a phase III randomised trial in stage III and IV ovarian cancer. J Clin Oncol 10: 706–717
Bookman M, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs J and Fields S (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16: 3345–3352
Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K and Colombo N (1994) European-Canadian randomised trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654–2666
Gordon A, Carmichael J, Malfetano Gore M, Spacynski M, Clarke-Pearson D, ten Bokkel Huinink WW, King K, Krebs J and Fields S (1998) Final analysis of a phase III, randomised study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma (OC): International Topotecan Study Group. Proc Am Soc Clin Oncol 17: A1374
Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci R and Blum R (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553–559
Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, Sorich J, Taubes B and Speyer J (1999) Activity and pharmacodynamics of 21 day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol 17: 2553–2561
Lorigan PC, Crosby T and Coleman RE (1996) Current drug treatment guidelines for epithelial ovarian cancer. Drugs 51: 571–584
Ozols RF, Hamilton TC, Hoskins WJ, Bast RC, Jr and Young RC (1991) Summary of symposium: Biology and Therapy of Ovarian Cancer. Semin Oncol 18: 297–306
Ozols RF, Rubin SC, Thomas GM and Robboy SJ (1997) Epithelial ovarian cancer. Hoskins WJ, Perez CA and Young RD (eds) Principles and Practice of Gynecologic Oncology, pp. 919–986, Lippincott: Philadelphia, PA
Rustin G, Nelstrop A, Benson S, Bond S and McClean P (2000) Selection of active drugs for ovarian cancer based on CA125 and standard response rates in phase II trials. J Clin Oncol 18: 1733–1739
ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spaczynski M, Bolis G, Malmstrom H, Coleman R, Fields S and Heron J (1997) Topotecan vs paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183–2193
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Gore, M., Rustin, G., Schüller, J. et al. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br J Cancer 84, 1043–1046 (2001). https://doi.org/10.1054/bjoc.2001.1726
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1726